Dimensional Fund Advisors LP Sells 109,300 Shares of Shattuck Labs, Inc. (NASDAQ:STTK)

Dimensional Fund Advisors LP trimmed its position in Shattuck Labs, Inc. (NASDAQ:STTK) by 63.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 62,956 shares of the company’s stock after selling 109,300 shares during the quarter. Dimensional Fund Advisors LP owned 0.13% of Shattuck Labs worth $76,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in STTK. JPMorgan Chase & Co. boosted its position in Shattuck Labs by 63.2% in the third quarter. JPMorgan Chase & Co. now owns 27,533 shares of the company’s stock valued at $96,000 after buying an additional 10,667 shares in the last quarter. Takeda Pharmaceutical Co. Ltd. acquired a new stake in Shattuck Labs in the fourth quarter valued at approximately $624,000. Barclays PLC boosted its position in Shattuck Labs by 299.5% in the third quarter. Barclays PLC now owns 54,311 shares of the company’s stock valued at $189,000 after buying an additional 40,717 shares in the last quarter. Virtu Financial LLC acquired a new stake in Shattuck Labs in the fourth quarter valued at approximately $30,000. Finally, Zacks Investment Management acquired a new stake in Shattuck Labs in the fourth quarter valued at approximately $25,000. 58.74% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have weighed in on STTK shares. Leerink Partners started coverage on shares of Shattuck Labs in a research report on Monday, March 17th. They issued an “outperform” rating and a $4.00 target price on the stock. HC Wainwright reiterated a “neutral” rating on shares of Shattuck Labs in a report on Thursday, March 27th. Needham & Company LLC reiterated a “hold” rating on shares of Shattuck Labs in a report on Thursday, March 27th. Finally, Leerink Partnrs upgraded shares of Shattuck Labs to a “strong-buy” rating in a report on Monday, March 17th. Four equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Shattuck Labs currently has a consensus rating of “Moderate Buy” and an average price target of $7.50.

Shattuck Labs Stock Performance

Shares of NASDAQ:STTK opened at $1.10 on Monday. The firm has a market cap of $52.69 million, a PE ratio of -0.72 and a beta of 1.74. The firm’s fifty day moving average is $0.98 and its 200-day moving average is $1.13. Shattuck Labs, Inc. has a 52 week low of $0.69 and a 52 week high of $8.15.

Shattuck Labs (NASDAQ:STTK) last announced its earnings results on Thursday, May 1st. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.02. Shattuck Labs had a negative net margin of 1,156.46% and a negative return on equity of 61.92%. Sell-side analysts forecast that Shattuck Labs, Inc. will post -1.48 EPS for the current year.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.